Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
Obodence (denosumab) has been authorised in the EU for osteoporosis and related bone resorption indications.
-
EMA approval · 2026-07-14EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
The EMA has authorised Bildyos (denosumab) by Sciencepharma Sp. z o.o. for bone resorption disorders including osteoporosis, including postm…
-
EMA approval · 2026-04-24EMA Authorised: Vysribli (previously Denosumab Intas) (denosumab) — Intas Third Party Sales 2005 S.L.
EMA authorised Vysribli (denosumab) for osteoporosis indications, including postmenopausal osteoporosis, with MAH Intas Third Party Sales 20…
-
EMA approval · 2026-04-20EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.
The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease …
-
EMA approval · 2026-03-20EMA Authorised: Evfraxy (denosumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Evfraxy (denosumab) as a biosimilar; it is approved for bone resorption disorders including osteoporosis and postmenopausal o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-04EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Kefdensis, a denosumab medicine by STADA Arzneimittel AG, for osteoporosis indications including po…
-
EMA approval · 2026-02-26EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence, a denosumab product from Fresenius Kabi Deutschland GmbH, for osteoporosis including postmenopausal osteoporosis.…
-
EMA approval · 2026-02-24EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
The European Medicines Agency has authorised Acvybra (denosumab) from Reddy Holding GmbH for osteoporosis-related conditions, including post…
-
EMA approval · 2026-02-12EMA Authorised: Fosavance (alendronic acid;colecalciferol) — Organon N.V.
EMA authorised Fosavance (alendronic acid and colecalciferol) by Organon N.V. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-02-12EMA Authorised: Adrovance (colecalciferol;alendronic acid (as sodium trihydrate)) — Organon N.V.
The European Medicines Agency authorised Adrovance, a fixed-dose combination of colecalciferol (vitamin D3) and alendronic acid (as sodium t…
-
EMA approval · 2026-02-12EMA Authorised: Vantavo (previously Alendronate sodium and colecalciferol, MSD) (alendronic acid;colecalciferol) — Organon N.V.
EMA authorised the medication Vantavo, a fixed combination of alendronic acid and colecalciferol, for postmenopausal osteoporosis, with Orga…
-
EMA approval · 2026-02-06EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
EMA authorised Bildyos, a denosumab medicine by Sciencepharma Sp. z o.o., for osteoporosis and postmenopausal osteoporosis related to bone r…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for ibandronate sodium by Macleods Pharmaceuticals Limited.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ibandronate sodium submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2026-02-03FDA Approved: FOSAMAX PLUS D — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Fosamax Plus D (alendronate sodium and cholecalciferol) submitted by Organon LLC.
-
FDA approval · 2026-02-03FDA Approved: ATELVIA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Atelvia (risendronate sodium) submitted by Allergan, Inc., to update/expand the product labeling…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' supplemental application for ibandronate sodium, indicating an updated approval status for t…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for ibandronate sodium filed by Apotex Corp., under ANDA 204222.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Ibandronate Sodium submitted by Mylan Institutional LLC.
-
EMA approval · 2026-01-30EMA Authorised: Osvyrti (denosumab) — Accord Healthcare S.L.U.
The EMA authorised Osvyrti, a denosumab product from Accord Healthcare S.L.U., for bone resorption disorders including osteoporosis and post…
-
EMA approval · 2026-01-28EMA Authorised: Forsteo (teriparatide) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Forsteo (teriparatide) for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-27EMA Authorised: Optruma (raloxifene hydrochloride) — Eli Lilly Nederland B.V.
The EMA authorised Optruma (raloxifene hydrochloride) from Eli Lilly Nederland B.V. for osteoporosis in postmenopausal women.
-
EMA approval · 2026-01-20EMA Authorised: Ponlimsi (denosumab) — Teva GmbH
The EMA authorised Ponlimsi (denosumab) by Teva GmbH on 19 January 2026 for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-14EMA Authorised: Stoboclo (denosumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Stoboclo (denosumab) by Celltrion Healthcare Hungary Kft. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-06EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
EMA authorised Obodence (denosumab) by Samsung Bioepis NL B.V. for osteoporosis, including postmenopausal osteoporosis.